1. Signaling Pathways
  2. Cell Cycle/DNA Damage
    Epigenetics
  3. PARP

PARP

PARP is a family of proteins involved in a number of cellular processes involving mainly DNA repair and programmed cell death. The PARP family comprises 17 members. They have all very different structures and functions in the cell. PARP1, PARP2, VPARP (PARP4), Tankyrase-1 and -2 (PARP-5a or TNKS, and PARP-5b or TNKS2) have a confirmed PARP activity. Others include PARP3, PARP6, TIPARP (or PARP7), PARP8, PARP9, PARP10, PARP11, PARP12, PARP14, PARP15, and PARP16. PARP is found in the cell’s nucleus. The main role is to detect and signal single-strand DNA breaks (SSB) to the enzymatic machinery involved in the SSB repair.

PARP Isoform Specific Products:

  • PARP

  • PARP1

  • PARP2

  • PARP3

  • PARP4

  • TNKS1/PARP5A

  • TNKS2/PARP5B

  • PARP10

  • PARP14

  • PARP7

PARP Related Products (65):

Cat. No. Product Name Effect Purity
  • HY-10162
    Olaparib Inhibitor 99.98%
    Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator.
  • HY-16106
    Talazoparib Inhibitor 99.89%
    Talazoparib (BMN-673) is a highly potent PARP1/2 inhibitor with Kis of 1.2 nM and 0.87 nM, respectively.
  • HY-10619
    Niraparib Inhibitor 99.97%
    Niraparib (MK-4827) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.
  • HY-15147
    XAV-939 Inhibitor 98.71%
    XAV-939 is a potent tankyrase inhibitor that targets Wnt/β-catenin signaling. XAV-939 stabilizes axin by inhibiting tankyrase 1 and tankyrase 2 (IC50s of 5 and 2 nM, respectively), thereby stimulating β-catenin degradation. XAV939 binds tightly to the catalytic (PARP) domains of TNKS1 and TNKS2 (Kds of 99 and 93 nM, respectively).
  • HY-10129
    Veliparib Inhibitor 99.47%
    Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with Kis of 5.2 and 2.9 nM, respectively.
  • HY-136174
    RBN-2397 Inhibitor
    RBN-2397 is a potent, accross species and orally active NAD+ competitive inhibitor of PARP7 (IC50<3 nM). RBN-2397 selectively binds to PARP7 (Kd=0.001 μM) and restores interferon (Type I) signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors.
  • HY-Z0283
    Benzamide Inhibitor
    Benzamide inhibits poly(ADP-ribose) polymerase (PARP).
  • HY-W015422
    1,5-Isoquinolinediol Inhibitor 99.33%
    1,5-Isoquinolinediol is a potent PARP inhibitor, with an IC50 of 0.18-0.37 µM. 1,5-Isoquinolinediol attenuates diabetes-induced NADPH oxidase-derived oxidative stress in retina.
  • HY-10617
    Rucaparib phosphate Inhibitor 99.89%
    Rucaparib phosphate (AG-014699 phosphate) is a potent and oral PARP inhibitor, with a Ki of 1.4 nM for PARP1 in cell-free assay, also showing binding affinity to eight other PARP domains.
  • HY-104044
    Pamiparib Inhibitor 99.97%
    Pamiparib (BGB-290) is an orally active, potent, highly selective PARP inhibitor, with IC50 values of 0.9 nM and 0.5 nM for PARP1 and PARP2, respectively. Pamiparib has oral bioavailability, potent PARP trapping, and capability to penetrate the brain, and can be used for the treatment of various cancers including the solid tumor.
  • HY-102003
    Rucaparib Camsylate Inhibitor 99.92%
    Rucaparib Camsylate is an inhibitor of PARP with a Ki of 1.4 nM for PARP1. Rucaparib Camsylate also shows binding affinity to eight other PARP domains.
  • HY-10619B
    Niraparib tosylate Inhibitor 99.81%
    Niraparib tosylate (MK-4827 tosylate) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with an IC50 of 3.8 and 2.1 nM, respectively. Niraparib tosylate (MK-4827 tosylate) leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.
  • HY-108413
    Talazoparib tosylate Inhibitor 99.74%
    Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available PARP1/2 inhibitor with an IC50 of 0.57 nM for PARP1.
  • HY-13688A
    PJ34 Inhibitor >98.0%
    PJ34 is a potent specific inhibitor of PARPl/2 with IC50 of 110 nM and 86 nM, respectively.
  • HY-13688
    PJ34 hydrochloride Inhibitor
    PJ34 hydrochloride is an inhibitor of PARP1/2 with IC50 of 110 nM and 86 nM, respectively.
  • HY-10130
    Veliparib dihydrochloride Inhibitor 99.62%
    Veliparib (dihydrochloride) is a potent inhibitor of PARP1 and PARP2 with Kis of 5.2 nM and 2.9 nM in cell-free assays, respectively.
  • HY-12438
    G007-LK Inhibitor 99.24%
    G007-LK is a potent and selective inhibitor of TNKS1 and TNKS2, with IC50s of 46 nM and 25 nM, respectively.
  • HY-12022
    3-Aminobenzamide Inhibitor 99.92%
    3-Aminobenzamide (PARP-IN-1) is a potent inhibitor of PARP with IC50 of appr 50 nM in CHO cells, and acts as a mediator of oxidant-induced myocyte dysfunction during reperfusion.
  • HY-12418
    E7449 Inhibitor >99.0%
    E7449 is a potent PARP1 and PARP2 inhibitor and also inhibits TNKS1 and TNKS2, with IC50s of 2.0, 1.0, ∼50 and ∼50 nM for PARP1, PARP2, TNKS1 and TNKS2, respectively, using 32P-NAD+ as substrate.
  • HY-12015
    Iniparib Inhibitor 99.87%
    Iniparib (BSI-201) is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.